AstraZeneca and Amgen are holding most of their cards close to the vest, but Phase III data they reported on 8 November may be adequate to file their anti-TSLP agent Tezspire (tezepelumab) for a second indication, in chronic rhinosinusitis with nasal polyps (CRSwNP). The drug met statistical significance in the WAYPOINT trial with clinically meaningful reduction of nasal polyp size and related nasal congestion.
Key Takeaways
- AstraZeneca and Amgen will seek to file Tezspire for nasal polyps related to chronic rhinosinusitis based on a successful Phase III trial.
The two companies are not providing numerical data from the 416-patient, placebo-controlled study as of yet, saying they will wait...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?